🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Australia / NCT06894836
Active, not recruiting Phase 2

Hybrid Type 2 Implementation-Effectiveness Trial of a Third Wave Virtual Reality Treatment for Youth Depression/Anxiety

NCT06894836 · tracked via the Priya Life Science Australia tracker
Sponsor
Phase
Phase 2
Started
2025-04-01
Last updated
2026-09-14

Condition(s) studied

Depression Anxiety Disorder

Investigational drug(s) / intervention(s)

Third wave VR therapy

Third wave VR therapy: All participants in this trial will receive the VR intervention which is adapted from third wave CBT protocols (including mindfulness and Acceptance and Commitment Therapy) and focuses on decentering-the ability to step back and view thoughts and emotions as temporary, objective events rather than identifying with them. Decentering has been linked to improved emotional regulation, reduced rumination, and better psychological flexibility, which in turn can lead to improvements in depression and anxiety symptoms. The intervention is clinician-delivered in a clinical setting, one-on-one, over 4-5 sessions (60 min each) across 10-12 weeks. Each session includes psychoeducation, a 15-minute VR experience, and debriefing. Sessions cover three core techniques targeting improvement in decentering ability: 1) arousal reduction via controlled breathing, 2) sitting with discomfort without reacting, and 3) cognitive defusion by changing perception of negative thoughts.

Study summary

This research will evaluate a new virtual reality (VR) intervention to support youth with depression and anxiety. While VR has shown promise for adult mental health, little is known about its use in youth or routine clinical care. The VR intervention is based on Acceptance and Commitment Therapy (ACT) and immerses young people in fun, engaging environments to teach practical coping skills for managing distress. Clinicians within youth mental health services will use the VR intervention within their routine treatment of young people. The study will evaluate both the preliminary effectiveness of the VR intervention for improving youth mental health, as well as real-world implementation outcomes to understand how it can be successfully adopted in clinical settings. The trial will use a single-group, pre-post design, with treating clinicians delivering the intervention to up to 75 young people seeking treatment for depression and anxiety over a 12-week period. Assessments will be conducted at baseline, immediately after the intervention (12 weeks), and four weeks post-intervention (16 weeks).

Eligibility

Sex
ALL
Min age
12 Years
Max age
25 Years
Healthy volunteers
No
There are three populations recruited for this trial: INCLUSION CRITERIA Young people 1. Aged between 12-25 years (inclusive) 2. Current client of a participating youth mental health service 3. Seeking or receiving treatment for depression and/or anxiety 4. Sufficient command of the English language Clinicians Employed at a participating youth mental health service and involved in the delivery of psychological treatment of young people presenting with depression and anxiety Service staff Work within a participating youth mental health service in a leadership (team lead or service manager) or administrative role. EXCLUSION CRITERIA: Young people 1. Moderate or severe audio or visual condition precluding engagement with the VR equipment (assessed on a case-by-case basis) 2. Counter indication based on clinical judgement e.g., active suicidal risk or intellectual disability. Clinicians Unable to commit to delivering the MIND intervention (5 sessions over 10-12 weeks). Service staff Nil

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Orygen, Centre for Youth Mental Health, University of Melbourne Parkville Victoria

More Orygen trials in Australia

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06894836 on ClinicalTrials.gov ↗ ← All trials in Australia